Rocket Pharmaceuticals (RCKT) clinical trials: pipeline and status changes, no readout expected in the next 12 months
$RCKT · Rocket Pharmaceuticals Inc.Trials that could report in the next 12 months: 0BiopharmaCTG
Catalyst timeline
No upcoming catalysts tracked for RCKT. Estimated readout windows appear automatically as tracked trials approach their registered completion dates.
Pipeline
| Program | Phase | Status | Primary completion | Trial |
|---|---|---|---|---|
| A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease | Phase 2 | Recruitingstill enrolling patients | NCT06092034 | |
| A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Vari… | Phase 1 | Recruitingstill enrolling patients | NCT05885412 | |
| Clinical Trial to Evaluate the Efficacy of Gene Therapy for Pyruvate K… | Phase 2 | Suspendedpaused | NCT06422351 | |
| A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Eff… | Phase 1 | Recruitingstill enrolling patients | NCT07137338 |
Status-change history
Every ClinicalTrials.gov change recorded for RCKT's trials — a running history no other tracker shows.
No status changes detected yet for this ticker.
Frequently asked
When is RCKT's next PDUFA date?
No disclosed PDUFA date is currently tracked for this ticker.
What phase is RCKT's lead program in?
Phase 2 — recruiting.
Where does this data come from?
ClinicalTrials.gov v2 API (trial status + diffs) and company 8-K/press-release disclosures (PDUFA dates). Every number links to its source.